Year: 2017

Pharmacogenetics can boost your chance of quitting smoking

The decision to quit smoking is a big step to improving your health. It is never too late to quit and the benefits include a reduction in cancer, heart and lung disease, and improved quality of life. When attempting to quit smoking,…

Read More

Ticagrelor pharmacogenetics: Low levels of evidence

Ticagrelor (Brilinta, Brilique, and Possia) is a platelet aggregation inhibitor used after a heart attack to prevent clots from forming and causing further heart attacks. At this moment, there no clear evidence for the use of pharmacogenetics for ticagrelor. PharmGKB, a…

Read More

TreatGx: Precision Prescribing Software

TreatGx is a precision prescribing software (medication decision support system) that personalizes prescriptions to help reduce the risk of adverse drug reactions, increase medication efficacy and reduce healthcare costs. TreatGx goes beyond the individual’s genetic code and enables precision prescribing by…

Read More

PharmGKB: Pharmacogenetic Database

PharmGKB is a publicly available internet research tool that provides information about how genetic variation among individuals contributes to differences in reactions to drugs. Developed by Stanford University and funded by the National Institutes of Health (NIH), PharmGKB is the largest…

Read More

Three new conditions now available in TreatGxplus

The team at GenXys is excited to announce that Gastroesophageal Reflux Disease, H. pylori Eradication and Dyspepsia/Peptic Ulcer Disease are now covered by TreatGxPlus (pharmacogenetic test and decision support system).   H. pylori Eradication   Helicobacter pylori is a bacterium that…

Read More

Metformin pharmacogenetics: The most up to date evidence does not support clinical use

The most up to date evidence does not support the use of SLC47A2 variants to predict glycemic response to metformin in diabetes Type 2 diabetes Type 2 diabetes is a chronic condition that affects the way the body metabolizes glucose (sugar)…

Read More

New conditions now available in TreatGxPlus

The team at Genxys is excited to announce that Post-Myocardial Infarction (Heart Attack) and Smoking Cessation are now covered in TreatGxPlus (pharmacogenetic test and decision support system). Post-Myocardial Infarction (Heart Attack) A myocardial infarction (MI) is also known as a heart…

Read More

How are the genes in the TreatGxPlus pharmacogenetic test selected?

The TreatGxPlus pharmacogenetic test was developed using an evidence-based approach, following a rigorous review process of scientific studies and professional guidelines. This process allows us to select genetic variants with strong evidence for a significant clinical outcome indicating a change in…

Read More

Lithium pharmacogenetics: Low levels of evidence

Genetic differences can cause a medication to work effectively in one person while failing to help, or even causing harm in another person. Pharmacogenetic testing detects these differences and can prevent adverse drug reactions (ADRs) and ineffective treatments. Pharmacogenomics is an…

Read More

Generation Genome – Department of Health England, CMO calls for the development and adoption of intelligent decision support systems in routine medical practice

Developments in information technology is vital to integrate genomic knowledge into electronic prescribing systems and facilitate adoption into practice The Chief Medical Officer (CMO) of the Department of Health England, Professor Dame Sally Davies, has called for making genomic testing part…

Read More